Global economic uncertainty and potential recession due to ongoing conflicts and downgraded growth forecasts could lead to a more risk-off investment environment, negatively impacting speculative, pre-revenue biotechnology companies like Acrivon Therapeutics. This affects their ability to raise capital for R&D.

Rising oil prices contributing to inflation and dampened global economic growth could further reduce investor appetite for high-risk assets, making it more challenging for Acrivon Therapeutics to attract necessary funding for its clinical development programs.

A strong US job market, while positive for the broader economy, may not directly benefit clinical-stage biopharmaceutical companies that are pre-revenue. However, a stable economy can foster a generally more confident investment climate, which might indirectly ease capital-raising efforts, though the prevailing risk-off sentiment from global factors could counteract this.